Design and validation of a ribosome display library for synthetic nanobody selection

Abstract

Single-domain antibodies (nanobodies) are compact, highly engineerable binding scaffolds widely used in structural biology, biotechnology, and therapeutics. When combined with the Legobody toolkit, they enable high-resolution cryo-electron microscopy (cryo-EM) analysis of small membrane proteins. Ribosome display is a powerful method for generating synthetic nanobodies (sybodies) with exceptionally high library diversity. However, existing sybody libraries are incompatible with the Legobody system, necessitating additional subcloning steps that reduce throughput and limit efficiency. Here, we report the rational design of a new ribosome-display-compatible nanobody library, termed S1.0, engineered for intrinsic compatibility with the Legobody platform through modifications in the C-terminal region. Compared to a benchmark sybody library, S1.0 features increased randomization in the complementarity-determining regions CDR1 and CDR3, while exhibiting reduced variability in CDR2. Selection against calmodulin demonstrated comparable efficiency to the benchmark library. Moreover, selection against thermostable green fluorescent protein (TGP) yielded multiple high-affinity sybodies, with nanomolar dissociation constants validated by size-exclusion chromatography and biolayer interferometry. Importantly, the selected sybodies are directly compatible with the Legobody system without requiring further engineering or subcloning. The S1.0 library represents a valuable resource for nanobody discovery and, in particular, provides an efficient route for generating Legobody-compatible binders suitable for structural studies of challenging small proteins by cryo-EM.

Keywords

Green fluorescence protein / Nanobody selection / Ribosome display / Single-chain antibody / Synthetic nanobody

References

[1] Ackle F, Thavarasah S, Earp JC, Seeger MA. Rigid enlargement of sybodies with antibody fragments for cryo-EM analyses of small membrane proteins. Sci Rep, 2025, 15: 9460

[2] Bloch JS, et al. Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins. Proc Natl Acad Sci U S A. 2021;118:e2115435118.

[3] Cai H, et al.. An improved fluorescent tag and its nanobodies for membrane protein expression, stability assay, and purification. Commun Biol, 2020, 3: 753

[4] Cai H, Yao H, Li T, Tang Y, Li D. High-level heterologous expression of the human transmembrane sterol Δ8,Δ7-isomerase in Pichia pastoris. Protein Expr Purif, 2019, 164: 105463

[5] Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics, 2018, 34: i884-i890

[6] Cong Y, Devoogdt N, Lambin P, Dubois LJ, Yaromina A. Promising diagnostic and therapeutic approaches based on VHHs for cancer management. Cancers (Basel). 2024;16:371.

[7] Cunningham S, et al.. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med, 2021, 9: 21-32

[8] Dörner T, et al.. FRI0239 results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. Ann Rheum Dis, 2017, 76: 575

[9] Doshi R, et al.. In vitro nanobody discovery for integral membrane protein targets. Sci Rep, 2014, 4: 6760

[10] Fan S, Gai C, Li B, Wang G. Efficacy and safety of Envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: a single‑arm meta‑analysis. Oncol Lett, 2023, 26: 351

[11] Fang Y, et al. Abstract 2857: DR30303, a SMART-VHHBody powered anti-CLDN18.2 VHH-Fc with enhanced ADCC activity for the treatment of gastric and pancreatic cancers. Cancer Res. 2022;82:2857–2857.

[12] Girard N, et al. Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors. JCO Oncol. Adv. 2025;2:e2400039.

[13] Guo M, et al.. Nanobodies-based colloidal gold immunochromatographic assay for specific detection of parathion. Anal Chim Acta, 2024, 1310: 342717

[14] Irobalieva RN, et al.. Structural basis of the allosteric inhibition of human ABCG2 by nanobodies. J Mol Biol, 2023, 435: 168234

[15] Kang W, et al.. Nanobody conjugates for targeted cancer therapy and imaging. Technol Cancer Res Treat, 2021, 20: 15330338211010117

[16] Kang Y, Chen L. Structural basis for the binding of DNP and purine nucleotides onto UCP1. Nature, 2023, 620: 226-231

[17] Kirchhofer A, et al.. Modulation of protein properties in living cells using nanobodies. Nat Struct Mol Biol, 2010, 17: 133-138

[18] Kondo T, et al.. Construction of a highly diverse mRNA library for in vitro selection of monobodies. Bio Protoc, 2021, 11: e4125

[19] Leeuw T, et al.. Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa. J Allergy Clin Immunol Glob, 2025, 4: 100483

[20] Li T, et al.. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. Nat Commun, 2021, 12: 4635

[21] Li T, et al.. Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2. Int J Biol Macromol, 2022, 209: 1379-1388

[22] Li T, et al.. Structural characterization of a neutralizing nanobody with broad activity against SARS-CoV-2 variants. Front Microbiol, 2022, 13: 875840

[23] Li T, et al.. Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. EMBO Mol Med, 2021, 13: e14544

[24] Li T, Cai H, Lai Y, Yao H, Li D. A simple and effective method to remove pigments from heterologous secretory proteins expressed in Pichia pastoris. Adv Biotechnol (Singap), 2024, 2: 5

[25] Li T, Zhou B, Dong H, Lavillette D, Li D. A human antibody derived from original SARS-CoV-2 infection effectively neutralizes Omicron. Adv Biotechnol, 2024, 2: 2

[26] Li Y, Gu W, Ni A, Li D, Li T. Screening and structural characterization of a nanobody targeting a thermostable green fluorescent protein. Acta Biochimica et Biophysica Sinica. 2026;online.

[27] Lin H, et al.. Structure and mechanism of the plastid/parasite ATP/ADP translocator. Nature, 2025, 641: 797-804

[28] Löw C, et al.. Nanobody mediated crystallization of an archeal mechanosensitive channel. PLoS ONE, 2013, 8: e77984

[29] McMahon C, et al.. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat Struct Mol Biol, 2018, 25: 289-296

[30] Mehra N, et al.. Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol, 2024, 42: TPS2672-TPS2672

[31] Muyldermans S. Applications of nanobodies. Annu Rev Anim Biosci, 2021, 9: 401-421

[32] Papp KA, Weinberg MA, Morris A, Reich K. IL17A/F nanobody Sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet, 2021, 397: 1564-1575

[33] Pardon E, et al.. A general protocol for the generation of nanobodies for structural biology. Nat Protoc, 2014, 9: 674-693

[34] Rasmussen SG, et al.. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature, 2011, 469: 175-180

[35] Redrado-Hernández S, et al.. Broad protection against invasive fungal disease from a nanobody targeting the active site of fungal β-1,3-Glucanosyltransferases. Angew Chem Int Ed Engl, 2024, 63: e202405823

[36] Schoof M, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370:1473-9.

[37] Scully M, et al.. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med, 2019, 380: 335-346

[38] Wang W, et al.. Nanobody-based PET imaging of CD47 expression in thyroid carcinoma. Mol Pharm, 2025, 22: 3414-3422

[39] Wang Z, et al. ALFA nanobody-guided endogenous labeling. Nat Chem Biol. 2025;21:1992-2001.

[40] Wu X, Rapoport TA. Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies). Proc Natl Acad Sci U S A, 2021, 118: e2115001118

[41] Xia B, et al. Phage-displayed synthetic library and screening platform for nanobody discovery. Elife. 2025;14;RP105887.

[42] Yang Z, et al.. Structural insights into auxin recognition and efflux by Arabidopsis PIN1. Nature, 2022, 609: 611-615

[43] Yao H, et al.. A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2. PLoS Pathog, 2021, 17: e1009328

[44] Yi S, et al.. Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation. Mol Cancer, 2025, 24: 124

[45] Yue Z, et al.. Structure-based design of covalent nanobody binders for a thermostable green fluorescence protein. Acta Biochim Biophys Sin (Shanghai), 2024, 57: 1363-1370

[46] Zhao Y, et al.. KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: a multicenter phase 2 trial. Cell Rep Med, 2024, 5: 101470

[47] Zimmermann I, et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. Elife. 2018;7:e34317.

Funding

National Natural Science Foundation of China(W2412096)

RIGHTS & PERMISSIONS

The Author(s)